Factors Influencing Utilization of the Primary Prevention Implantable Defibrillator

被引:5
|
作者
Zhang, Lin [1 ]
Narayanan, Kumar [2 ]
Chugh, Harpriya [2 ]
Shiota, Takahiro [2 ]
Zheng, Zhi-Jie [1 ]
Chugh, Sumeet S. [2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Publ Hlth, Shanghai 200030, Peoples R China
[2] Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA
来源
PLOS ONE | 2015年 / 10卷 / 03期
关键词
SUDDEN CARDIAC DEATH; CARDIOVERTER-DEFIBRILLATORS; HEART-FAILURE; PROPHYLACTIC IMPLANTATION; EJECTION FRACTION; NATIONAL-SURVEY; UNITED-STATES; GUIDELINES; THERAPY; SEX;
D O I
10.1371/journal.pone.0121515
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background A growing literature suggests underutilization of the primary prevention implantable cardioverter-defibrillator (ICD); thus, factors influencing utilization need to be understood. We performed a comprehensive assessment of patient characteristics and health insurance status among subjects eligible for primary prevention ICD in a tertiary care center. Methods From among a group of patients who met criteria for primary prevention ICD based on left ventricular dysfunction (LVEF <= 35%), ICD recipients (n = 110) were compared to ICD non-recipients (n = 110) to identify determinants of ICD implantation. We evaluated demographics, clinical profile including Charlson Comorbidity Index [CCI, categorized as low (<= 3) or high (> 3)] and health insurance status. Results ICD recipients were younger (62.1+/-15.0 vs. 68.0+/-18.2; P = 0.01), with more males (80% vs. 65.5%; P = 0.01), higher NYHA class (II/III: 75.5% vs. 40.2%; P< 0.001) and more likely to have supplemental private health insurance (61.8% vs. 46.4%; P = 0.02). CCI was not significantly different between the two groups (low CCI 61.8% vs. 62.7%; P = 0.89). In multivariable analysis, factors independently associated with ICD implantation were male sex (OR, 2.77, [1.31-5.85]; P = 0.01), age< 75 (OR, 2.68, [1.30-5.50]; P = 0.01), private insurance (OR, 2.17, [1.08-4.36], P = 0.03) and NYHA Class II/III (OR, 5.91, [2.91-12.01]; P< 0.001). Documentation of discussion about primary prevention ICD was absent in the majority (57.2%) of non-recipients. Conclusion In a contemporary urban tertiary care setting, age, sex and heart failure symptom class were associated with ICD utilization, with socioeconomic/insurance status also potentially playing a role. These findings have implications for optimizing appropriate utilization of the prophylactic ICD and warrant follow-up in larger, more diverse populations.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The implantable defibrillator in primary prevention in elderly patients
    Vetta, Francesco
    Vetta, Giampaolo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2020, 21 (10) : 790 - 800
  • [2] Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy
    Nauffal, Victor
    Marstrand, Peter
    Han, Larry
    Parikh, Victoria N.
    Helms, Adam S.
    Ingles, Jodie
    Jacoby, Daniel
    Lakdawala, Neal K.
    Kapur, Sunil
    Michels, Michelle
    Owens, Anjali T.
    Ashley, Euan A.
    Pereira, Alexandre C.
    Rossano, Joseph W.
    Saberi, Sara
    Semsarian, Christopher
    Ware, James S.
    Wittekind, Samuel G.
    Day, Sharlene
    Olivotto, Iacopo
    Ho, Carolyn Y.
    EUROPEAN HEART JOURNAL, 2021, 42 (38) : 3932 - 3944
  • [3] Gender Differences in Implantable Cardioverter-Defibrillator Utilization for Primary Prevention of Sudden Cardiac Death
    Garima Dahiya
    Jane Chen
    Current Treatment Options in Cardiovascular Medicine, 2021, 23
  • [4] Gender Differences in Implantable Cardioverter-Defibrillator Utilization for Primary Prevention of Sudden Cardiac Death
    Dahiya, Garima
    Chen, Jane
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2021, 23 (12)
  • [5] Syncope in Primary Prevention Implantable Cardioverter Defibrillator Patients
    Goldenberg, Gustavo
    Bental, Tamir
    Kadmon, Udi
    Zabarsky, Ronit
    Kusnick, Jairo
    Barsheshet, Mon
    Golovchiner, Gregory
    Strasberg, Boris
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2016, 18 (06): : 318 - 321
  • [6] Syncope in Primary Prevention Implantable Cardioverter Defibrillator Implantation
    Goldenberg, Gustavo
    Bental, Tamir
    Kadmon, Udi
    Zabarsky, Ronit
    Kusnick, Jairo
    Barsheshet, Alon
    Golovchiner, Gregory
    Strasberg, Boris
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2017, 19 (01): : 15 - 18
  • [7] Recent primary prevention implantable cardioverter defibrillator trials
    Duray, G
    Israel, CW
    Hohnloser, SH
    CURRENT OPINION IN CARDIOLOGY, 2006, 21 (01) : 15 - 19
  • [8] How Overall Health Status and Insurance Influence Utilization of the Primary Prevention Implantable Defibrillator in the Current Era
    Zhang, Lin
    Narayanan, Kumar
    Chugh, Harpriya
    Takahiro, Shiota
    Zheng, Zhi-Jie
    Chugh, Sumeet S.
    CIRCULATION, 2014, 130
  • [9] Cardiac implantable defibrillator in primary prevention: predictors of appropriate therapy
    Marta Braga, M.
    Nascimento, H.
    Ribeiro, V.
    Melao, F.
    Oliveira, S. M.
    Vasconcelos, M.
    Dias, P.
    Frutuoso, C.
    Maciel, M. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 377 - 377
  • [10] Update on primary prevention implantable cardioverter-defibrillator therapy
    Epstein A.E.
    Current Cardiology Reports, 2009, 11 (5) : 335 - 342